Company research / BLGO

Biolargo, Inc. (BLGO)

SEC name BIOLARGO, INC. · CIK 0000880242 · OTC · Chemicals & Allied Products

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Biolargo, Inc. reported revenue of $7.76M. Revenue fell 56.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $4.08M.

Key ratios (year ended 2025-12-31)

43.9%
Gross margin
-191.3%
Operating margin
-195.6%
Net margin
-375.8%
Return on year-end equity
-56.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form DEF 14A (proxy statement) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.08M$7.76M$17.78M$12.23M$5.88M$2.53M$2.43M$1.86M$1.36M$516.0K$281.1K
Cost of Revenue$2.45M$4.36M$9.93M$6.08M$3.03M$1.43M$1.20M$945.0K$743.0K$323.0K$105.9K
Gross Profit$1.63M$3.41M$7.85M$6.15M$2.86M$1.10M$1.23M$916.0K$621.0K$193.0K$175.2K
R&D Expense$3.26M$2.59M$2.88M$2.28M$1.32M$1.37M$1.34M$1.47M$1.72M$1.63M$1.38M
Operating Income-$18.12M-$14.86M-$4.33M-$4.58M-$5.39M-$6.78M-$7.58M-$6.70M-$6.41M-$5.90M-$4.93M
Depreciation & Amortizationn/an/an/a$103.0K$45.0K$20.0K$58.0K$65.0K$50.0K$30.0K$15.9K
EBITDAn/an/an/a-$4.48M-$5.34M-$6.76M-$7.53M-$6.63M-$6.36M-$5.87M-$4.92M
Net Income-$18.79M-$15.19M-$4.35M-$4.65M-$5.13M-$6.89M-$9.70M-$11.44M-$10.70M-$9.55M-$8.07M
Total Assets$6.67M$8.31M$10.51M$8.21M$4.86M$3.02M$4.94M$3.62M$3.19M$1.50M$2.11M
Total Liabilities$9.40M$6.79M$4.46M$4.00M$2.85M$2.09M$5.18M$5.80M$4.31M$4.91M$2.88M
Long-Term Debtn/a$2.08M$1.08Mn/an/an/an/an/an/an/a$5.86M
Shareholders' Equity-$1.85M$4.04M$8.85M$6.84M$4.88M$4.65M$3.86M-$2.15M-$1.50M-$4.10M-$1.33M
Cash & Equivalents$2.19M$3.88M$3.55M$3.54M$1.85M$962.0K$716.0K$655.0K$655.0K$990.0K$1.91M
Operating Cash Flow-$10.32M-$8.30M-$3.21M-$2.37M-$2.76M-$3.94M-$4.15M-$4.42M-$3.89M-$4.28M-$3.72M
Capital Expendituresn/an/an/an/an/an/an/an/an/a$28.7Kn/a
Free Cash Flown/an/an/an/an/an/an/an/an/a-$4.31Mn/a
Shares Outstandingn/an/an/a292.95M278.46Mn/an/an/an/an/a92.98M
EPS (Basic)n/a-$0.04-$0.01-$0.01-$0.02-$0.03n/an/an/an/an/a